Dong Wha Pharm signs exclusive sales agreement of FDA-approved adhesive barrier with Genzyme Korea

Published: 2017-03-06 11:46:55

Updated: 2017-03-06 11:46:55

Dong Wha Pharm(Chairman Doh-Joon Yoon) signed an exclusive distribution and sales agreement of the deep-cavity wound dressing Seprafilm(adhesion barrier) to Korea with the Sanofi Group’s corporate body of specialty care, Genzyme Korea(CEO Hee-Kyung Park).

Under the agreement, Dong Wha Pharm will take charge in the entire distribution, sales and marketing of the product from January 2017.

Sepr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.